The Pullback Is Overdone. Abiomed Is Now A Strong Buy

About: Abiomed, Inc. (ABMD)
by: Jeff Ross
This article is exclusive for subscribers.
Jeff Ross
Hedge fund manager, registered investment advisor, long/short equity, healthcare

Abiomed is a pioneer and market-leading medical device company for circulatory support.

Abiomed's groundbreaking products are seeing growing adoption in the US and around the world, and this should continue for the foreseeable future.

The share price of ABMD has declined 20% since its recent high, which offers a compelling entry point for the long-term investor.

Vailshire Partners LP is long ABMD.

Abiomed (ABMD) remains relatively unknown among investors, yet it has a market capitalization of nearly $16B and is a leading provider of circulatory support medical devices. A steep drawdown following its recent quarterly